COMMISSION IMPLEMENTING REGULATION (EU) 2018/1647
of 31 October 2018
authorising the placing on the market of egg membrane hydrolysate as a novel food under Regulation (EU) 2015/2283 of the European Parliament and of the Council and amending Commission Implementing Regulation (EU) 2017/2470
(Text with EEA relevance)
Article 1
Article 2
Article 3
Article 4
ANNEX
Authorised novel food |
Conditions under which the novel food may be used |
Additional specific labelling requirements |
Other requirements |
Data Protection |
|
‘Egg membrane hydrolysate |
Specified food category |
Maximum levels |
The designation of the novel food on the labelling of the foodstuffs containing it shall be “egg membrane hydrolysate”. |
|
Authorised on 25 November 2018. This inclusion is based on proprietary scientific evidence and scientific data protected in accordance with Article 26 of Regulation (EU) 2015/2283. Applicant: Biova, LLC., 5800 Merle Hay Rd, Suite 14 PO Box 394 Johnston 50131, Iowa USA. During the period of data protection the novel food egg membrane hydrolysate is authorised for placing on the market within the Union only by Biova, LLC. unless a subsequent applicant obtains authorisation for the novel food without reference to the proprietary scientific evidence or scientific data protected in accordance with Article 26 of Regulation (EU) 2015/2283 or with the agreement of Biova, LLC. End date of the data protection: 25 November 2023’. |
Food Supplements as defined in Directive 2002/46/EC intended for the general adult population |
450 mg/day |
Authorised Novel Food |
Specification |
|
‘Egg membrane hydrolysate |
Description The egg membrane hydrolysate is derived from the eggshell membranes of chicken eggs. The eggshells undergo hydro-mechanical separation in order to obtain the egg membranes, which are then further processed using a patented solubilisation method. Following the solubilisation process, the solution is filtered, concentrated, spray-dried and packaged. Characteristics/Composition |
|
Chemical parameters |
Methods |
|
Total nitrogen-containing compounds (% w/w): ≥ 88 |
Combustion according to AOAC 990.03 and AOAC 992.15 |
|
Collagen (% w/w): ≥ 15 |
SircolTM Soluble Collagen Assay |
|
Elastin (% w/w): ≥ 20 |
FastinTM Elastin Assay |
|
Total glycosaminoglycans (% w/w): ≥ 5 |
USP26 (chondroitin sulphate K0032 method) |
|
Calcium: ≤ 1 % |
|
|
Physical parameters pH: 6,5 – 7,6 Ash (% w/w): ≤ 8 Moisture (% w/w): ≤ 9 Water activity: ≤ 0,3 Solubility (in water): soluble Bulk density: ≥ 0,6 g/cc Heavy metals Arsenic ≤ 0,5 mg/kg Microbiological criteria Aerobic plate count: ≤ 2 500 CFU/g Escherichia coli: ≤ 5 MPN/g Salmonella: Negative (in 25 g) Coliforms: ≤ 10 MPN/g Staphylococcus aureus: ≤ 10 CFU/g Mesophilic spore count: ≤ 25 CFU/g Thermophilic spore count: ≤ 10 CFU/10 g Yeast: ≤ 10 CFU/g Mould: ≤ 200 CFU/g CFU: Colony Forming Units; MPN = Most Probable Number; USP: United States Pharmacopeia.’ |